The approval of Jemperli (dostarlimab-gxly) + carboplatin + paclitaxel, followed by Jemperli as monotx. for the treatment of adult patients with dMMR primary advanced or recurrent endometrial cancer
This approval is based on the interim analysis results from Part 1 of the P-III study (RUBY), which demonstrated a median duration of follow-up of ≥25mos. A significant and clinically meaningful benefit in PFS and a 71% reduction in the risk of disease progression or death. The trial continues to evaluate OS
Consistent safety and tolerability were seen over the monotherapies. The most common TEAEs were ≥20%. Also, the data were presented at ESMO and SGO 2023 and published in The New England Journal of Medicine.
Ref: Businesswire| Image: GSK
Related News:- GSK Reports the US FDA Acceptance of sBLA for Jemperli (dostarlimab) to Treat dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
